Implications of Medicare Negotiation and Most-Favored-Nation Pricing for Cancer Medicine Costs

This cross-sectional study explores expenditures, negotiated pricing, and potential additional savings for top-selling cancer products in Medicare Part B and Part D.

Corresponding Author: Thomas J. Hwang, MD, Cancer Innovation and Regulation Initiative, Brigham and Women's Hospital, 41 Avenue Louis Pasteur, Boston, MA 02115 (tjhwang@post.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.